IFN-β and multiple sclerosis: Cross-talking of immune cells and integration of immunoregulatory networks

Cytokine and Growth Factor Reviews

Volumn 26, Issue 2, 2015, Pages 229-239

  Severa, Martina ^a   Rizzo, Fabiana ^a   Giacomini, Elena ^a   Salvetti, Marco ^b   Coccia, Eliana M ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Bystander immune regulation; IFN therapy; Immune cell subsets; Multiple sclerosis

Indexed keywords

B CELL ACTIVATING FACTOR; BETA INTERFERON; BETA1A INTERFERON; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR5; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; INTERFERON BETA SERINE; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 27; MITOXANTRONE; MYELIN BASIC PROTEIN; NATALIZUMAB; OLIGOCLONAL BAND; PEGINTERFERON BETA1A; PROTEOLIPID PROTEIN; TERIFLUNOMIDE; TOLL LIKE RECEPTOR 7; ANTIVIRUS AGENT;

ANTIVIRAL ACTIVITY; B LYMPHOCYTE; BYSTANDER EFFECT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COMMUNICATION; CYTOKINE PRODUCTION; DENDRITIC CELL; EPSTEIN BARR VIRUS INFECTION; GENE EXPRESSION REGULATION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INTRACELLULAR SIGNALING; LYMPHOCYTE FUNCTION; MOLECULAR INTERACTION; MONOCYTE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; REGULATORY T LYMPHOCYTE; RETROVIRUS INFECTION; SHORT SURVEY; T LYMPHOCYTE SUBPOPULATION; TH1 TH2 BALANCE; TH17 CELL; DISEASE COURSE; IMMUNOLOGY;

ANTIVIRAL AGENTS; B-LYMPHOCYTES; DENDRITIC CELLS; DISEASE PROGRESSION; HUMANS; IMMUNOMODULATION; INTERFERON-BETA; MONOCYTES; MULTIPLE SCLEROSIS;

EID: 84926513526     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2014.11.005     Document Type: Short Survey

References (113)

1. Minagar A. Current and future therapies for multiple sclerosis. Scientifica (Cairo) 2013, 2013:249101.
2. Kieseier B.C. The mechanism of action of interferon-beta in relapsing multiple sclerosis. CNS Drugs 2011, 25:491-502.
3. Isaacs A., Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957, 147:258-267.
4. Hardy M.P., Owczarek C.M., Jermiin L.S., Ejdeback M., Hertzog P.J. Characterization of the type I interferon locus and identification of novel genes. Genomics 2004, 84:331-345.
5. Severa M., Fitzgerald K.A. TLR-mediated activation of type I IFN during antiviral immune responses: fighting the battle to win the war. Curr Top Microbiol Immunol 2007, 316:167-192.
6. Maniatis T., Falvo J.V., Kim T.H., Kim T.K., Lin C.H., Parekh B.S., et al. Structure and function of the interferon-beta enhanceosome. Cold Spring Harb Symp Quant Biol 1998, 63:609-620.
7. Honda K., Takaoka A., Taniguchi T. Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity 2006, 25:349-360.
8. Fitzgerald K.A., McWhirter S.M., Faia K.L., Rowe D.C., Latz E., Golenbock D.T., et al. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol 2003, 4:491-496.
9. Hiscott J., Nguyen T.L., Arguello M., Nakhaei P., Paz S. Manipulation of the nuclear factor-kappaB pathway and the innate immune response by viruses. Oncogene 2006, 25:6844-6867.
10. Uze G., Schreiber G., Piehler J., Pellegrini S. The receptor of the type I interferon family. Curr Top Microbiol Immunol 2007, 316:71-95.
11. Borden E.C., Sen G.C., Uze G., Silverman R.H., Ransohoff R.M., Foster G.R., et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 2007, 6:975-990.
12. de Veer M.J., Holko M., Frevel M., Walker E., Der S., Paranjape J.M., et al. Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol 2001, 69:912-920.
13. Ransohoff R.M., Brown M.A. Innate immunity in the central nervous system. J Clin Invest 2012, 122:1164-1171.
14. Mirandola S.R., Hallal D.E., Farias A.S., Oliveira E.C., Brandao C.O., Ruocco H.H., et al. Interferon-beta modifies the peripheral blood cell cytokine secretion in patients with multiple sclerosis. Int Immunopharmacol 2009, 9:824-830.
15. Rudick R.A., Ransohoff R.M., Lee J.C., Peppler R., Yu M., Mathisen P.M., et al. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology 1998, 50:1294-1300.
16. Ramgolam V.S., Sha Y., Jin J., Zhang X., Markovic-Plese S. IFN-beta inhibits human Th17 cell differentiation. J Immunol 2009, 183:5418-5427.
17. Avolio C., Filippi M., Tortorella C., Rocca M.A., Ruggieri M., Agosta F., et al. Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. Mult Scler 2005, 11:441-446.
18. Defazio G., Gelati M., Corsini E., Nico B., Dufour A., Massa G., et al. In vitro modulation of adhesion molecules, adhesion phenomena, and fluid phase endocytosis on human umbilical vein endothelial cells and brain-derived microvascular endothelium by IFN-beta 1a. J Interferon Cytokine Res 2001, 21:267-272.
19. Stuve O., Dooley N.P., Uhm J.H., Antel J.P., Francis G.S., Williams G., et al. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 1996, 40:853-863.
20. Jin S., Kawanokuchi J., Mizuno T., Wang J., Sonobe Y., Takeuchi H., et al. Interferon-beta is neuroprotective against the toxicity induced by activated microglia. Brain Res 2007, 1179:140-146.
21. Biernacki K., Antel J.P., Blain M., Narayanan S., Arnold D.L., Prat A. Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis. Arch Neurol 2005, 62:563-568.
22. Ascherio A., Munger K.L. Environmental risk factors for multiple sclerosis. Part I: The role of infection. Ann Neurol 2007, 61:288-299.
23. Lunemann J.D., Munz C. EBV in MS: guilty by association. Trends Immunol 2009, 30:243-248.
24. Serafini B., Rosicarelli B., Franciotta D., Magliozzi R., Reynolds R., Cinque P., et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 2007, 204:2899-2912.
25. Serafini B., Severa M., Columba-Cabezas S., Rosicarelli B., Veroni C., Chiappetta G., et al. Epstein-Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation. J Neuropathol Exp Neurol 2010, 69:677-693.
26. Wucherpfennig K.W., Strominger J.L. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995, 80:695-705.
27. Mycko M.P., Waldner H., Anderson D.E., Bourcier K.D., Wucherpfennig K.W., Kuchroo V.K., et al. Cross-reactive TCR responses to self antigens presented by different MHC class II molecules. J Immunol 2004, 173:1689-1698.
28. Pender M.P. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol 2003, 24:584-588.
29. Perron H., Perin J.P., Rieger F., Alliel P.M. Particle-associated retroviral RNA and tandem RGH/HERV-W copies on human chromosome 7q: possible components of a 'chain-reaction' triggered by infectious agents in multiple sclerosis?. J Neurovirol 2000, 6(Suppl. 2):S67-S75.
30. Hsiao F.C., Lin M., Tai A., Chen G., Huber B.T. Cutting edge: Epstein-Barr virus transactivates the HERV-K18 superantigen by docking to the human complement receptor 2 (CD21) on primary B cells. J Immunol 2006, 177:2056-2060.
31. Dreyfus D.H. Autoimmune disease: a role for new anti-viral therapies. Autoimmun Rev 2011, 11:88-97.
32. Sospedra M., Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005, 23:683-747.
33. Pette M., Fujita K., Wilkinson D., Altmann D.M., Trowsdale J., Giegerich G., et al. Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors. Proc Natl Acad Sci U S A 1990, 87:7968-7972.
34. Anderson A.C., Nicholson L.B., Legge K.L., Turchin V., Zaghouani H., Kuchroo V.K. High frequency of autoreactive myelin proteolipid protein-specific T cells in the periphery of naive mice: mechanisms of selection of the self-reactive repertoire. J Exp Med 2000, 191:761-770.
35. Imam S.A., Guyton M.K., Haque A., Vandenbark A., Tyor W.R., Ray S.K., et al. Increased calpain correlates with Th1 cytokine profile in PBMCs from MS patients. J Neuroimmunol 2007, 190:139-145.
36. O'Shea J.J., Visconti R. Type 1 IFNs and regulation of TH1 responses: enigmas both resolved and emerge. Nat Immunol 2000, 1:17-19.
37. Babbe H., Roers A., Waisman A., Lassmann H., Goebels N., Hohlfeld R., et al. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 2000, 192:393-404.
38. Lossius A., Johansen J.N., Vartdal F., Robins H., Jurate Saltyte B., Holmoy T., et al. High-throughput sequencing of TCR repertoires in multiple sclerosis reveals intrathecal enrichment of EBV-reactive CD8(+) T cells. Er J Immunol 2014, 44:3439-3452.
39. Killestein J., Eikelenboom M.J., Izeboud T., Kalkers N.F., Ader H.J., Barkhof F., et al. Cytokine producing CD8+ T cells are correlated to MRI features of tissue destruction in MS. J Neuroimmunol 2003, 142:141-148.
40. Angelini D.F., Serafini B., Piras E., Severa M., Coccia E.M., Rosicarelli B., et al. Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis. PLoS Pathog 2013, 9:e1003220.
41. Cua D.J., Sherlock J., Chen Y., Murphy C.A., Joyce B., Seymour B., et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421:744-748.
42. Annunziato F., Cosmi L., Santarlasci V., Maggi L., Liotta F., Mazzinghi B., et al. Phenotypic and functional features of human Th17 cells. J Exp Med 2007, 204:1849-1861.
43. Hedegaard C.J., Krakauer M., Bendtzen K., Lund H., Sellebjerg F., Nielsen C.H. T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis. Immunology 2008, 125:161-169.
44. Sallusto F., Zielinski C.E., Lanzavecchia A. Human Th17 subsets. Eur J Immunol 2012, 42:2215-2220.
45. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002, 8:500-508.
46. Matusevicius D., Kivisakk P., He B., Kostulas N., Ozenci V., Fredrikson S., et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999, 5:101-104.
47. Ransohoff R.M., Kivisakk P., Kidd G. Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol 2003, 3:569-581.
48. Tzartos J.S., Friese M.A., Craner M.J., Palace J., Newcombe J., Esiri M.M., et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008, 172:146-155.
49. Kebir H., Kreymborg K., Ifergan I., Dodelet-Devillers A., Cayrol R., Bernard M., et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 2007, 13:1173-1175.
50. Balasa R., Bajko Z., Hutanu A. Serum levels of IL-17A in patients with relapsing-remitting multiple sclerosis treated with interferon-beta. Mult Scler 2013, 19:885-890.
51. Kvarnstrom M., Ydrefors J., Ekerfelt C., Vrethem M., Ernerudh J. Longitudinal interferon-beta effects in multiple sclerosis: differential regulation of IL-10 and IL-17A, while no sustained effects on IFN-gamma, IL-4 or IL-13. J Neurol Sci 2013, 325:79-85.
52. Krakauer M., Sorensen P., Khademi M., Olsson T., Sellebjerg F. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression. Mult Scler 2008, 14:622-630.
53. Zhang X., Jin J., Tang Y., Speer D., Sujkowska D., Markovic-Plese S. IFN-beta1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulation. J Immunol 2009, 182:3928-3936.
54. Franciotta D., Salvetti M., Lolli F., Serafini B., Aloisi F. B cells and multiple sclerosis. Lancet Neurol 2008, 7:852-858.
55. Bar-Or A., Calabresi P.A., Arnold D., Markowitz C., Shafer S., Kasper L.H., et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 2008, 63:395-400.
56. Stuve O., Leussink V.I., Frohlich R., Hemmer B., Hartung H.P., Menge T., et al. Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis. Arch Neurol 2009, 66:259-261.
57. Gay D., Esiri M. Blood-brain barrier damage in acute multiple sclerosis plaques. An immunocytological study. Brain 1991, 114(Pt 1B):557-572.
58. Owens G.P., Bennett J.L., Lassmann H., O'Connor K.C., Ritchie A.M., Shearer A., et al. Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann Neurol 2009, 65:639-649.
59. Obermeier B., Lovato L., Mentele R., Bruck W., Forne I., Imhof A., et al. Related B cell clones that populate the CSF and CNS of patients with multiple sclerosis produce CSF immunoglobulin. J Neuroimmunol 2011, 233:245-248.
60. Krumbholz M., Theil D., Cepok S., Hemmer B., Kivisakk P., Ransohoff R.M., et al. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 2006, 129:200-211.
61. Sellebjerg F., Bornsen L., Khademi M., Krakauer M., Olsson T., Frederiksen J.L., et al. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology 2009, 73:2003-2010.
62. Aloisi F., Serafini B., Magliozzi R., Howell O.W., Reynolds R. Detection of Epstein-Barr virus and B-cell follicles in the multiple sclerosis brain: what you find depends on how and where you look. Brain 2010, 133:e157.
63. Magliozzi R., Howell O., Vora A., Serafini B., Nicholas R., Puopolo M., et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007, 130:1089-1104.
64. Young L.S., Rickinson A.B. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004, 4:757-768.
65. Haas J., Bekeredjian-Ding I., Milkova M., Balint B., Schwarz A., Korporal M., et al. B cells undergo unique compartmentalized redistribution in multiple sclerosis. J Autoimmun 2011, 37:289-299.
66. Petereit H.F., Moeller-Hartmann W., Reske D., Rubbert A. Rituximab in a patient with multiple sclerosis - effect on B cells, plasma cells and intrathecal IgG synthesis. Acta Neurol Scand 2008, 117:399-403.
67. Duddy M.E., Alter A., Bar-Or A. Distinct profiles of human B cell effector cytokines: a role in immune regulation. J Immunol 2004, 172:3422-3427.
68. Lund F.E., Garvy B.A., Randall T.D., Harris D.P. Regulatory roles for cytokine-producing B cells in infection and autoimmune disease. Curr Dir Autoimmun 2005, 8:25-54.
69. Fillatreau S., Sweenie C.H., McGeachy M.J., Gray D., Anderton S.M. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002, 3:944-950.
70. Mauri C., Gray D., Mushtaq N., Londei M. Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 2003, 197:489-501.
71. Bar-Or A., Fawaz L., Fan B., Darlington P.J., Rieger A., Ghorayeb C., et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS. Ann Neurol 2010, 67:452-461.
72. Jiang H., Milo R., Swoveland P., Johnson K.P., Panitch H., Dhib-Jalbut S. Interferon beta-1b reduces interferon gamma-induced antigen-presenting capacity of human glial and B cells. J Neuroimmunol 1995, 61:17-25.
73. Ramgolam V.S., Sha Y., Marcus K.L., Choudhary N., Troiani L., Chopra M., et al. B cells as a therapeutic target for IFN-beta in relapsing-remitting multiple sclerosis. J Immunol 2011, 186:4518-4526.
74. Giacomini E., Severa M., Rizzo F., Mechelli R., Annibali V., Ristori G., et al. IFN-beta therapy modulates B-cell and monocyte crosstalk via TLR7 in multiple sclerosis patients. Eur J Immunol 2013, 43:1963-1972.
75. Krumbholz M., Faber H., Steinmeyer F., Hoffmann L.A., Kumpfel T., Pellkofer H., et al. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 2008, 131:1455-1463.
76. Ganguly D., Haak S., Sisirak V., Reizis B. The role of dendritic cells in autoimmunity. Nat Rev Immunol 2013, 13:566-577.
77. Olsson T., Holmdahl R., Klareskog L., Forsum U. Ia-expressing cells and T lymphocytes of different subsets in peripheral nerve tissue during experimental allergic neuritis in Lewis rats. Scand J Immunol 1983, 18:339-343.
78. Knight S.C., Mertin J., Stackpoole A., Clark J. Induction of immune responses in vivo with small numbers of veiled (dendritic) cells. Proc Natl Acad Sci U S A 1983, 80:6032-6035.
79. Lande R., Gafa V., Serafini B., Giacomini E., Visconti A., Remoli M.E., et al. Plasmacytoid dendritic cells in multiple sclerosis: intracerebral recruitment and impaired maturation in response to interferon-beta. J Neuropathol Exp Neurol 2008, 67:388-401.
80. Serafini B., Rosicarelli B., Magliozzi R., Stigliano E., Capello E., Mancardi G.L., et al. Dendritic cells in multiple sclerosis lesions: maturation stage, myelin uptake, and interaction with proliferating T cells. J Neuropathol Exp Neurol 2006, 65:124-141.
81. Severa M., Giacomini E., Gafa V., Anastasiadou E., Rizzo F., Corazzari M., et al. EBV stimulates TLR- and autophagy-dependent pathways and impairs maturation in plasmacytoid dendritic cells: implications for viral immune escape. Eur J Immunol 2013, 43:147-158.
82. Pashenkov M., Huang Y.M., Kostulas V., Haglund M., Soderstrom M., Link H. Two subsets of dendritic cells are present in human cerebrospinal fluid. Brain 2001, 124:480-492.
83. Longhini A.L., von Glehn F., Brandao C.O., de Paula R.F., Pradella F., Moraes A.S., et al. Plasmacytoid dendritic cells are increased in cerebrospinal fluid of untreated patients during multiple sclerosis relapse. J Neuroinflammation 2011, 8:2.
84. Karni A., Abraham M., Monsonego A., Cai G., Freeman G.J., Hafler D., et al. Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J Immunol 2006, 177:4196-4202.
85. Lopez C., Comabella M., Al-zayat H., Tintore M., Montalban X. Altered maturation of circulating dendritic cells in primary progressive MS patients. J Neuroimmunol 2006, 175:183-191.
86. Vaknin-Dembinsky A., Murugaiyan G., Hafler D.A., Astier A.L., Weiner H.L. Increased IL-23 secretion and altered chemokine production by dendritic cells upon CD46 activation in patients with multiple sclerosis. J Neuroimmunol 2008, 195:140-145.
87. Stasiolek M., Bayas A., Kruse N., Wieczarkowiecz A., Toyka K.V., Gold R., et al. Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis. Brain 2006, 129:1293-1305.
88. Schwab N., Zozulya A.L., Kieseier B.C., Toyka K.V., Wiendl H. An imbalance of two functionally and phenotypically different subsets of plasmacytoid dendritic cells characterizes the dysfunctional immune regulation in multiple sclerosis. J Immunol 2010, 184:5368-5374.
89. Bayas A., Stasiolek M., Kruse N., Toyka K.V., Selmaj K., Gold R. Altered innate immune response of plasmacytoid dendritic cells in multiple sclerosis. Clin Exp Immunol 2009, 157:332-342.
90. Hirotani M., Niino M., Fukazawa T., Yaguchi H., Nakamura M., Kikuchi S., et al. Decreased interferon-alpha production in response to CpG DNA dysregulates cytokine responses in patients with multiple sclerosis. Clin Immunol 2012, 143:145-151.
91. de Andres C., Aristimuno C., Bartolome M., de Las Heras V., Martinez-Gines M.L., Arroyo R., et al. Clinical response to interferon-beta-1a may be linked to low baseline circulating BDCA1 myeloid dendritic cells Differential role of circulating dendritic cells and CD4+ regulatory T-cells in relapsing-remitting multiple sclerosis: a 1-year longitudinal study. J Neuroimmunol 2009, 212:112-120.
92. Huang Y.M., Stoyanova N., Jin Y.P., Teleshova N., Hussien Y., Xiao B.G., et al. Altered phenotype and function of blood dendritic cells in multiple sclerosis are modulated by IFN-beta and IL-10. Clin Exp Immunol 2001, 124:306-314.
93. Aung L.L., Fitzgerald-Bocarsly P., Dhib-Jalbut S., Balashov K. Plasmacytoid dendritic cells in multiple sclerosis: chemokine and chemokine receptor modulation by interferon-beta. J Neuroimmunol 2010, 226:158-164.
94. Balashov K.E., Aung L.L., Vaknin-Dembinsky A., Dhib-Jalbut S., Weiner H.L. Interferon-beta inhibits Toll-like receptor 9 processing in multiple sclerosis. Ann Neurol 2010, 68:899-906.
95. Aung L.L., Brooks A., Greenberg S.A., Rosenberg M.L., Dhib-Jalbut S., Balashov K.E. Multiple sclerosis-linked and interferon-beta-regulated gene expression in plasmacytoid dendritic cells. J Neuroimmunol 2012, 250:99-105.
96. Shi C., Pamer E.G. Monocyte recruitment during infection and inflammation. Nat Rev Immunol 2011, 11:762-774.
97. Yamasaki R., Lu H., Butovsky O., Ohno N., Rietsch A.M., Cialic R., et al. Differential roles of microglia and monocytes in the inflamed central nervous system. J Exp Med 2014, 211:1533-1549.
98. Trebst C., Konig F., Ransohoff R., Bruck W., Stangel M. CCR5 expression on macrophages/microglia is associated with early remyelination in multiple sclerosis lesions. Mult Scler 2008, 14:728-733.
99. Lisak R.P., Nedelkoska L., Studzinski D., Bealmear B., Xu W., Benjamins J.A. Cytokines regulate neuronal gene expression: differential effects of Th1, Th2 and monocyte/macrophage cytokines. J Neuroimmunol 2011, 238:19-33.
100. Ifergan I., Kebir H., Bernard M., Wosik K., Dodelet-Devillers A., Cayrol R., et al. The blood-brain barrier induces differentiation of migrating monocytes into Th17-polarizing dendritic cells. Brain 2008, 131:785-799.
101. Savard M., Belanger C., Tardif M., Gourde P., Flamand L., Gosselin J. Infection of primary human monocytes by Epstein-Barr virus. J Virol 2000, 74:2612-2619.
102. Brudek T., Christensen T., Aagaard L., Petersen T., Hansen H.J., Moller-Larsen A. B cells and monocytes from patients with active multiple sclerosis exhibit increased surface expression of both HERV-H Env and HERV-W Env, accompanied by increased seroreactivity. Retrovirology 2009, 6:104.
103. Johnston J.B., Silva C., Holden J., Warren K.G., Clark A.W., Power C. Monocyte activation and differentiation augment human endogenous retrovirus expression: implications for inflammatory brain diseases. Ann Neurol 2001, 50:434-442.
104. Kouwenhoven M., Teleshova N., Ozenci V., Press R., Link H. Monocytes in multiple sclerosis: phenotype and cytokine profile. J Neuroimmunol 2001, 112:197-205.
105. Gandhi K.S., McKay F.C., Schibeci S.D., Arthur J.W., Heard R.N., Stewart G.J., et al. BAFF is a biological response marker to IFN-beta treatment in multiple sclerosis. J Interferon Cytokine Res 2008, 28:529-539.
106. Gavasso S., Mosleth E.F., Maroy T., Jorgensen K., Nakkestad H.L., Gjertsen B.T., et al. Deficient phosphorylation of Stat1 in leukocytes identifies neutralizing antibodies in multiple sclerosis patients treated with interferon-beta. PLOS ONE 2014, 9:e88632.
107. Johnson T.P., Tyagi R., Patel K., Schiess N., Calabresi P.A., Nath A. Impaired Toll-like receptor 8 signaling in multiple sclerosis. J Neuroinflammation 2013, 10:74.
108. Comabella M., Lunemann J.D., Rio J., Sanchez A., Lopez C., Julia E., et al. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain 2009, 132:3353-3365.
109. Bustamante M.F., Nurtdinov R.N., Rio J., Montalban X., Comabella M. Baseline gene expression signatures in monocytes from multiple sclerosis patients treated with interferon-beta. PLOS ONE 2013, 8:e60994.
110. Zula J.A., Green H.C., Ransohoff R.M., Rudick R.A., Stark G.R., van Boxel-Dezaire A.H. The role of cell type-specific responses in IFN-beta therapy of multiple sclerosis. Proc Natl Acad Sci U S A 2011, 108:19689-19694.
111. Prinz M., Schmidt H., Mildner A., Knobeloch K.P., Hanisch U.K., Raasch J., et al. Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 2008, 28:675-686.
112. Vandenbark A.A., Huan J., Agotsch M., La Tocha D., Goelz S., Offner H., et al. Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis. J Neuroimmunol 2009, 215:125-128.
113. Jego G., Palucka A.K., Blanck J.P., Chalouni C., Pascual V., Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003, 19:225-234.